Transplant Cell Ther. 2024 Mar 30:S2666-6367(24)00301-4. doi: 10.1016/j.jtct.2024.03.028. Online ahead of print.
ABSTRACT
BACKGROUND: While curing a patient’s underlying disease is the primary goal of physicians performing hematopoietic cell transplantation (HCT), the ultimate objective is to provide patients with optimal post-HCT quality of life. For many survivors, this includes returning to work (RTW).
OBJECTIVE: We conducted a survey of one- to five-year post-HCT survivors at our center to evaluate their perspective on facilitators and barriers to RTW as well as to gauge interest in potentially useful RTW support interventions.
STUDY DESIGN: Survivors aged 18 to 65 years (n=994) were sent an annual survey that included 36 supplementary questions about post-HCT RTW. Survey questions were selected from published national cancer survivor surveys and then modified specifically for HCT survivors.
RESULTS: 344 (35%) survivors with a mean age of 53 years completed the survey, of whom 272 (79%) had worked prior to their diagnosis. Of those 272 patients, 145 (53%) were working currently and another 22 (8%) had attempted to go back to work following HCT but were not presently working. We found that having had an allogeneic vs autologous HCT (p=0.006) was associated with a decreased likelihood of currently working, whereas frequent employer communication (> once a month) (p=0.070) and having a more supportive employer (p=0.036) were associated with a greater chance of currently working. Of survivors currently working, 45% reported that they had made one or more changes to their work schedule (e.g., flexible schedule or part-time work) or environment (e.g., work from home) upon RTW. Ninety-five percent of responders reported that they could have benefited from RTW support provided by the transplant center, but only 13% indicated that they had received it. Education on RTW challenges, information on disability benefits, and access to physical therapy were among the most requested support interventions.
CONCLUSION: To improve post-HCT quality of life for survivors open to assistance, providers should address work status and goals, recognize barriers to successful return, and offer RTW support including working directly with employers. Allogeneic HCT survivors are particularly vulnerable to failing attempts to RTW and should be the target of retention interventions. A previously published manuscript on RTW guidance for providers of stem cell transplant patients endorsed by the American Society of Transplant and Cellular Therapy is available Open Access and can be used as a tool to counsel and support these patients.
PMID:38561139 | DOI:10.1016/j.jtct.2024.03.028
